These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 24899687

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
    Hoang LN, McConechy MK, Köbel M, Han G, Rouzbahman M, Davidson B, Irving J, Ali RH, Leung S, McAlpine JN, Oliva E, Nucci MR, Soslow RA, Huntsman DG, Gilks CB, Lee CH.
    Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
    [Abstract] [Full Text] [Related]

  • 23. The diagnostic role of PTEN and ARID1A in serous effusions.
    Davidson B, Pinamonti M, Cuevas D, Holth A, Zeppa P, Hager T, Wohlschlaeger J, Tötsch M.
    Virchows Arch; 2018 Mar; 472(3):425-432. PubMed ID: 29170871
    [Abstract] [Full Text] [Related]

  • 24. ARID1A Regulates Progesterone Receptor Expression in Early Endometrial Endometrioid Carcinoma Pathogenesis.
    Asaka S, Liu Y, Yu ZC, Rahmanto YS, Ono M, Asaka R, Miyamoto T, Yen TT, Ayhan A, Wang TL, Shih IM.
    Mod Pathol; 2023 Feb; 36(2):100045. PubMed ID: 36853791
    [Abstract] [Full Text] [Related]

  • 25. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
    Chandler RL, Damrauer JS, Raab JR, Schisler JC, Wilkerson MD, Didion JP, Starmer J, Serber D, Yee D, Xiong J, Darr DB, Pardo-Manuel de Villena F, Kim WY, Magnuson T.
    Nat Commun; 2015 Jan 27; 6():6118. PubMed ID: 25625625
    [Abstract] [Full Text] [Related]

  • 26. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas.
    Catasús L, Bussaglia E, Rodrguez I, Gallardo A, Pons C, Irving JA, Prat J.
    Hum Pathol; 2004 Nov 27; 35(11):1360-8. PubMed ID: 15668893
    [Abstract] [Full Text] [Related]

  • 27. PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression.
    Tanwar PS, Kaneko-Tarui T, Lee HJ, Zhang L, Teixeira JM.
    Carcinogenesis; 2013 Apr 27; 34(4):893-901. PubMed ID: 23276799
    [Abstract] [Full Text] [Related]

  • 28. ARID1A gene mutation in ovarian and endometrial cancers (Review).
    Takeda T, Banno K, Okawa R, Yanokura M, Iijima M, Irie-Kunitomi H, Nakamura K, Iida M, Adachi M, Umene K, Nogami Y, Masuda K, Kobayashi Y, Tominaga E, Aoki D.
    Oncol Rep; 2016 Feb 27; 35(2):607-13. PubMed ID: 26572704
    [Abstract] [Full Text] [Related]

  • 29. Alternate molecular genetic pathways in ovarian carcinomas of common histological types.
    Willner J, Wurz K, Allison KH, Galic V, Garcia RL, Goff BA, Swisher EM.
    Hum Pathol; 2007 Apr 27; 38(4):607-13. PubMed ID: 17258789
    [Abstract] [Full Text] [Related]

  • 30. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.
    Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, Fearon ER, Cho KR.
    Cancer Cell; 2007 Apr 27; 11(4):321-33. PubMed ID: 17418409
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Common genetic changes between endometriosis and ovarian cancer.
    Obata K, Hoshiai H.
    Gynecol Obstet Invest; 2000 Apr 27; 50 Suppl 1():39-43. PubMed ID: 11093060
    [Abstract] [Full Text] [Related]

  • 33. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
    Heckl M, Schmoeckel E, Hertlein L, Rottmann M, Jeschke U, Mayr D.
    PLoS One; 2018 Apr 27; 13(2):e0192881. PubMed ID: 29451900
    [Abstract] [Full Text] [Related]

  • 34. [An approach to early genetic alterations in precancerous cells].
    Sato N, Nishida M, Noguchi M.
    Hum Cell; 2000 Sep 27; 13(3):103-8. PubMed ID: 11197771
    [Abstract] [Full Text] [Related]

  • 35. Impact of oviductal versus ovarian epithelial cell of origin on ovarian endometrioid carcinoma phenotype in the mouse.
    Wu R, Zhai Y, Kuick R, Karnezis AN, Garcia P, Naseem A, Hu TC, Fearon ER, Cho KR.
    J Pathol; 2016 Nov 27; 240(3):341-351. PubMed ID: 27538791
    [Abstract] [Full Text] [Related]

  • 36. The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.
    Goldman AR, Bitler BG, Schug Z, Conejo-Garcia JR, Zhang R, Speicher DW.
    Mol Cell Proteomics; 2016 Nov 27; 15(11):3348-3360. PubMed ID: 27654507
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Mammalian target of rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt/β-catenin and PTEN.
    Tanwar PS, Zhang L, Kaneko-Tarui T, Curley MD, Taketo MM, Rani P, Roberts DJ, Teixeira JM.
    PLoS One; 2011 Nov 27; 6(6):e20715. PubMed ID: 21695255
    [Abstract] [Full Text] [Related]

  • 40. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
    Samartzis EP, Noske A, Dedes KJ, Fink D, Imesch P.
    Int J Mol Sci; 2013 Sep 12; 14(9):18824-49. PubMed ID: 24036443
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.